RCKT Stock Forecast: Rocket Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Rocket Pharmaceuticals, Inc. is $9.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Rocket Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (82): Sales and profits are climbing, and climbing faster than before.
Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
RCKT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RCKT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Nov 2026 | Chardan Capital | Maintains | Buy | $11 |
| 8 Oct 2026 | Goldman Sachs | Upgrade | Neutral | $3.00 → $4.00 |
| 7 Oct 2026 | Chardan Capital | Maintains | Buy | $11 |
| 7 Oct 2026 | Leerink Partners | Maintains | Market Perform | $7.00 → $4.00 |
| 7 Oct 2026 | Wedbush | Reiterates | Outperform | $15 |
| 16 Sept 2026 | Needham | Upgrade | Buy | $9.00 |
| 16 Sept 2026 | Wedbush | Reiterates | Outperform | $15 |
| 15 Sept 2026 | Chardan Capital | Maintains | Buy | $11 |
| 1 Sept 2026 | Chardan Capital | Maintains | Buy | $11 |
| 11 Aug 2026 | Wedbush | Maintains | Outperform | $16 → $15 |
| 11 May 2026 | Chardan Capital | Maintains | Buy | $11 |
| 30 Mar 2026 | B of A Securities | Maintains | Buy | — |
| 27 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 2 Mar 2026 | Goldman Sachs | Maintains | Sell | — |
| 27 Feb 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 18 Nov 2025 | B of A Securities | Maintains | Buy | — |
| 18 Nov 2025 | JP Morgan | Downgrade | Underweight | — |
| 14 Oct 2025 | Chardan Capital | Maintains | Buy | — |
| 3 Oct 2025 | Leerink Partners | Maintains | Market Perform | — |
| 20 Aug 2025 | B of A Securities | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RCKT.
This page is one stock. Monday covers all of them.
RCKT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
RCKT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Rocket Pharmaceuticals, Inc. returned −31.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
RCKT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 79% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −5.0%
- Return on assets
- −30.2%
- Dividend yield
- —
Higher than 40% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rocket Pharmaceuticals, Inc. has a market value of $235.6M and an enterprise value of $21.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$17.3M.
Diluted earnings per share, trailing twelve months: −$0.17.
Free cash flow in the twelve months to 30 June 2026: −$170.4M.
Rocket Pharmaceuticals, Inc. employs 202 people.
Data provided by Twelve Data
RCKT and its peers
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| RCKTRocket Pharmaceuticals, Inc. | $235.6M | 36 |
| ARCTArcturus Therapeutics Holdings, Inc. | $211.7M | 74 |
| IPSCCentury Therapeutics, Inc. | $209.3M | 44 |
| ALLOAllogene Therapeutics, Inc. | $207.9M | 45 |
| PYXSPyxis Oncology, Inc. | $216.2M | 74 |
| DTILPrecision BioSciences, Inc. | $204.3M | 81 |
| KROSKeros Therapeutics, Inc. | $218.5M | 83 |
Take a look at RCKT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Rocket Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about RCKT
What is the RCKT stock price forecast for 2026-2027?
The median 12-month analyst price target for Rocket Pharmaceuticals, Inc. is $9.5, with estimates ranging from $2.75 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RCKT stock a buy right now?
Of the 14 analysts covering Rocket Pharmaceuticals, Inc., 7 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Rocket Pharmaceuticals, Inc. 36 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RCKT?
As at 21 Nov 2026, Rocket Pharmaceuticals, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (82 of 100).
Will RCKT stock go up?
No one can know that. What the data says: the median 12-month target from 14 analysts is $9.5, and Ticker Nerd's factor model ranks Rocket Pharmaceuticals, Inc. 36 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RCKT stock forecast for 2030?
No analyst covering Rocket Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RCKT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.75 to $15 over the next 12 months.
How has RCKT stock performed over the past year?
Rocket Pharmaceuticals, Inc. returned -31.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Rocket Pharmaceuticals, Inc. do?
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology. The company’s programs are built around advanced viral vector platforms designed to address the underlying genetic cause of serious pediatric and inherited conditions.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology. The company’s programs are built around advanced viral vector platforms designed to address the underlying genetic cause of serious pediatric and inherited conditions. Rocket Pharmaceuticals currently develops and advances investigational and commercial genetic medicines, including therapies for disorders such as Danon disease, BAG3-related dilated cardiomyopathy, Fanconi anemia, and severe leukocyte adhesion deficiency-I. The company is also involved in manufacturing, clinical development, and the commercialization of its gene therapy products. Headquartered in Cranbury, New Jersey, Rocket Pharmaceuticals plays a specialized role in the rare-disease market by targeting conditions with significant unmet medical need through precision genetic medicine.
CEO Dr. Gaurav D. Shah M.D. · 202 employees · United States · https://www.rocketpharma.com